JP2020504741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504741A5 JP2020504741A5 JP2019534245A JP2019534245A JP2020504741A5 JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5 JP 2019534245 A JP2019534245 A JP 2019534245A JP 2019534245 A JP2019534245 A JP 2019534245A JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- substituted
- ulm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*)N(*)C(C(*)NC(C(C)N)=O)=O Chemical compound CC(*)N(*)C(C(*)NC(C(C)N)=O)=O 0.000 description 48
- DERXELLTUOVDQH-UHFFFAOYSA-N CN(C1)CC1F Chemical compound CN(C1)CC1F DERXELLTUOVDQH-UHFFFAOYSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CC(C)C(NC)=O Chemical compound CC(C)C(NC)=O IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 2
- ZAMXVCJJAQXCBT-UHFFFAOYSA-N CN(CC1)CC1F Chemical compound CN(CC1)CC1F ZAMXVCJJAQXCBT-UHFFFAOYSA-N 0.000 description 2
- YNZOOJLMTULUQT-XNWIYYODSA-N CN(CCC1)C1C(C1)N(C)C[C@@H]1F Chemical compound CN(CCC1)C1C(C1)N(C)C[C@@H]1F YNZOOJLMTULUQT-XNWIYYODSA-N 0.000 description 2
- VDOLWAQYIDIFME-WHFBIAKZSA-N CN(C[C@@H]1O)C[C@@H]1F Chemical compound CN(C[C@@H]1O)C[C@@H]1F VDOLWAQYIDIFME-WHFBIAKZSA-N 0.000 description 2
- SHAHSPDXKLHDNO-NKVNRFPTSA-N C[C@H](C[C@H]1F)C1C1N(C)CCCC1 Chemical compound C[C@H](C[C@H]1F)C1C1N(C)CCCC1 SHAHSPDXKLHDNO-NKVNRFPTSA-N 0.000 description 2
- KDSAXEOLUPBMBT-UHFFFAOYSA-N C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 KDSAXEOLUPBMBT-UHFFFAOYSA-N 0.000 description 1
- RCOAYXFWTLIZRE-UHFFFAOYSA-N CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O RCOAYXFWTLIZRE-UHFFFAOYSA-N 0.000 description 1
- ZTAZUQNGWKMQMQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O ZTAZUQNGWKMQMQ-UHFFFAOYSA-N 0.000 description 1
- AGHUJPNOYUMQSV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O AGHUJPNOYUMQSV-UHFFFAOYSA-N 0.000 description 1
- HFJDGWPENBIHKK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O HFJDGWPENBIHKK-UHFFFAOYSA-N 0.000 description 1
- KARHZPCIVJWKRD-MUUNZHRXSA-N CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O KARHZPCIVJWKRD-MUUNZHRXSA-N 0.000 description 1
- VTKNFMYABFTAQP-ZFGGDYGUSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O VTKNFMYABFTAQP-ZFGGDYGUSA-N 0.000 description 1
- MGFBAMQBZTVJRS-UJSFRCSHSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O MGFBAMQBZTVJRS-UJSFRCSHSA-N 0.000 description 1
- SRGDAQPTGJKAMK-RUDCESOPSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O SRGDAQPTGJKAMK-RUDCESOPSA-N 0.000 description 1
- NEJPPXZUWGFBDL-HTCXSVJXSA-N CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 Chemical compound CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 NEJPPXZUWGFBDL-HTCXSVJXSA-N 0.000 description 1
- SXFWBOTXORQGJN-UHFFFAOYSA-N CC(C)CCC(NC)=O Chemical compound CC(C)CCC(NC)=O SXFWBOTXORQGJN-UHFFFAOYSA-N 0.000 description 1
- IYDMGGPKSVWQRT-XZWHSSHBSA-N CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl Chemical compound CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl IYDMGGPKSVWQRT-XZWHSSHBSA-N 0.000 description 1
- CWWBCISTWBLCMI-CGYACHGYSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O CWWBCISTWBLCMI-CGYACHGYSA-N 0.000 description 1
- FEWHVHJXHQNNTR-LFRRGIFHSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O FEWHVHJXHQNNTR-LFRRGIFHSA-N 0.000 description 1
- VBGCXCMUKOYHJF-RZUBCFFCSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 VBGCXCMUKOYHJF-RZUBCFFCSA-N 0.000 description 1
- YQOGFIVOLUHWKC-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 YQOGFIVOLUHWKC-BAGYTPMASA-N 0.000 description 1
- GFRBMXSURJKHGR-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 GFRBMXSURJKHGR-HSALFYBXSA-N 0.000 description 1
- IHDWHNABLZYBIH-CZHRTVMISA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 IHDWHNABLZYBIH-CZHRTVMISA-N 0.000 description 1
- NMQOREDOOXJWIK-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 NMQOREDOOXJWIK-HSALFYBXSA-N 0.000 description 1
- UAOHBORKFLZBPO-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 UAOHBORKFLZBPO-HSALFYBXSA-N 0.000 description 1
- YYSFFVIJGUQALQ-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 YYSFFVIJGUQALQ-BAGYTPMASA-N 0.000 description 1
- GJGXQAODWZABIH-DMTNHVFBSA-N CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O Chemical compound CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O GJGXQAODWZABIH-DMTNHVFBSA-N 0.000 description 1
- YKABBFAFVRCVPP-AULYBMBSSA-N CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O Chemical compound CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O YKABBFAFVRCVPP-AULYBMBSSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- GCEWJCVKPTZCRU-UHFFFAOYSA-N CCC1OC1NC Chemical compound CCC1OC1NC GCEWJCVKPTZCRU-UHFFFAOYSA-N 0.000 description 1
- QKGZBDBAWVAAKZ-UHFFFAOYSA-N CCCC(CCC)CCC(NC)=O Chemical compound CCCC(CCC)CCC(NC)=O QKGZBDBAWVAAKZ-UHFFFAOYSA-N 0.000 description 1
- QNEGXSQWCRRYSN-QPJOQSLLSA-N CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O Chemical compound CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O QNEGXSQWCRRYSN-QPJOQSLLSA-N 0.000 description 1
- JNSRQBZQGWFBKE-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O JNSRQBZQGWFBKE-UHFFFAOYSA-N 0.000 description 1
- DWLFNIVXWUHBJQ-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O DWLFNIVXWUHBJQ-UHFFFAOYSA-N 0.000 description 1
- QXMBWAUFPOAKNN-OQKACKPTSA-N CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O QXMBWAUFPOAKNN-OQKACKPTSA-N 0.000 description 1
- RTRZHLJEMYASNC-HJZXASKDSA-N CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O RTRZHLJEMYASNC-HJZXASKDSA-N 0.000 description 1
- KDUOPPMIWCFSEU-UHFFFAOYSA-N CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O KDUOPPMIWCFSEU-UHFFFAOYSA-N 0.000 description 1
- VDOLWAQYIDIFME-UHFFFAOYSA-N CN(CC1O)CC1F Chemical compound CN(CC1O)CC1F VDOLWAQYIDIFME-UHFFFAOYSA-N 0.000 description 1
- LCQASUWGXZDLLK-FXLOMAGBSA-N CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O LCQASUWGXZDLLK-FXLOMAGBSA-N 0.000 description 1
- VDOLWAQYIDIFME-BRJRFNKRSA-N CN(C[C@H]1O)CC1F Chemical compound CN(C[C@H]1O)CC1F VDOLWAQYIDIFME-BRJRFNKRSA-N 0.000 description 1
- LARRZJQWINEIFU-UHFFFAOYSA-N CN1CC(CCN2CCNCC2)CC1 Chemical compound CN1CC(CCN2CCNCC2)CC1 LARRZJQWINEIFU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UPIHZCDTQBTGHI-UHFFFAOYSA-N CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 Chemical compound CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 UPIHZCDTQBTGHI-UHFFFAOYSA-N 0.000 description 1
- DYGHSFRVQSBDJP-RXMQYKEDSA-N CS(N(CC1)C[C@@H]1F)(=O)=O Chemical compound CS(N(CC1)C[C@@H]1F)(=O)=O DYGHSFRVQSBDJP-RXMQYKEDSA-N 0.000 description 1
- UATHGXSVZBAWEK-JFHPQLLQSA-N C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC UATHGXSVZBAWEK-JFHPQLLQSA-N 0.000 description 1
- IBBHIZXRMBKKII-IYNDAXALSA-N C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC IBBHIZXRMBKKII-IYNDAXALSA-N 0.000 description 1
- AADMRSQDLRYQQU-UHFFFAOYSA-N Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 AADMRSQDLRYQQU-UHFFFAOYSA-N 0.000 description 1
- NKJLAVFMTFUYGP-UHFFFAOYSA-N Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 NKJLAVFMTFUYGP-UHFFFAOYSA-N 0.000 description 1
- PXRKWVGPKRKKFP-UHFFFAOYSA-N Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 PXRKWVGPKRKKFP-UHFFFAOYSA-N 0.000 description 1
- CCGOLKRCFVKMCO-UHFFFAOYSA-N Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 CCGOLKRCFVKMCO-UHFFFAOYSA-N 0.000 description 1
- BOECVYQYFLWQNP-UHFFFAOYSA-N Cc1cc(COCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCCN2CCN(C)CC2)n[o]1 BOECVYQYFLWQNP-UHFFFAOYSA-N 0.000 description 1
- OFOLFJNDUSEUPT-UHFFFAOYSA-N Cc1cc(COCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCN2CCN(C)CC2)n[o]1 OFOLFJNDUSEUPT-UHFFFAOYSA-N 0.000 description 1
- LTCXOHTXCPOVIV-UMSPYCQHSA-N Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 Chemical compound Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 LTCXOHTXCPOVIV-UMSPYCQHSA-N 0.000 description 1
- QEBVSEQGCUZGCV-SECBINFHSA-N Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 QEBVSEQGCUZGCV-SECBINFHSA-N 0.000 description 1
- UQPSXJLSPRHBBA-OQWWRJADSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 UQPSXJLSPRHBBA-OQWWRJADSA-N 0.000 description 1
- CFJMFGGNHCSIHD-VRPJDWIJSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 CFJMFGGNHCSIHD-VRPJDWIJSA-N 0.000 description 1
- RQPANKYMENZMFC-PHVLXYFRSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 RQPANKYMENZMFC-PHVLXYFRSA-N 0.000 description 1
- KGZUGSKPAMJRRC-UHFFFAOYSA-N O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 Chemical compound O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 KGZUGSKPAMJRRC-UHFFFAOYSA-N 0.000 description 1
- DXQDVHBZWPXJPA-UHFFFAOYSA-N O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O DXQDVHBZWPXJPA-UHFFFAOYSA-N 0.000 description 1
- CCERGJGFOODHOI-NDEPHWFRSA-N O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O CCERGJGFOODHOI-NDEPHWFRSA-N 0.000 description 1
- UTSZNJIEZABRKU-OAQYLSRUSA-N O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 UTSZNJIEZABRKU-OAQYLSRUSA-N 0.000 description 1
- RFWLATFOOGPHAS-AREMUKBSSA-N OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O RFWLATFOOGPHAS-AREMUKBSSA-N 0.000 description 1
- SJCTVMPUXINNPA-UHFFFAOYSA-N OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O SJCTVMPUXINNPA-UHFFFAOYSA-N 0.000 description 1
- YEFDWSQVRHOJFI-UHFFFAOYSA-N OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 Chemical compound OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 YEFDWSQVRHOJFI-UHFFFAOYSA-N 0.000 description 1
- PKXOFPCXFBCGEA-MECOZAJYSA-N OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O PKXOFPCXFBCGEA-MECOZAJYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015526A JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438803P | 2016-12-23 | 2016-12-23 | |
| US62/438,803 | 2016-12-23 | ||
| US201762582698P | 2017-11-07 | 2017-11-07 | |
| US62/582,698 | 2017-11-07 | ||
| PCT/US2017/068322 WO2018119448A1 (en) | 2016-12-23 | 2017-12-22 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Division JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504741A JP2020504741A (ja) | 2020-02-13 |
| JP2020504741A5 true JP2020504741A5 (enExample) | 2021-02-04 |
| JP7679173B2 JP7679173B2 (ja) | 2025-05-19 |
Family
ID=62625473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534245A Active JP7679173B2 (ja) | 2016-12-23 | 2017-12-22 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10723717B2 (enExample) |
| EP (1) | EP3558994A4 (enExample) |
| JP (3) | JP7679173B2 (enExample) |
| KR (3) | KR20250117470A (enExample) |
| CN (2) | CN110741004B (enExample) |
| AU (2) | AU2017382436C1 (enExample) |
| BR (1) | BR112019012878A2 (enExample) |
| CA (1) | CA3047784A1 (enExample) |
| CO (1) | CO2019007894A2 (enExample) |
| IL (4) | IL325835A (enExample) |
| MX (2) | MX2019007649A (enExample) |
| WO (1) | WO2018119448A1 (enExample) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2767532T3 (en) | 2012-12-21 | 2016-09-12 | Nat Inst For Quantum And Radiological Science And Tech | New connection for reproduction of tau protein heavy in the brain. |
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| AU2018258581A1 (en) * | 2017-04-28 | 2019-11-07 | Quartz Therapeutics, Inc. | RAF-degrading conjugate compounds |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019094773A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2019196812A1 (zh) * | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| IL302595A (en) * | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| TW201946624A (zh) | 2018-05-09 | 2019-12-16 | 新旭生技股份有限公司 | 雜芳基化合物及其用途 |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| JP7472103B2 (ja) | 2018-08-22 | 2024-04-22 | クルゲン（シャンハイ），インク． | トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法 |
| IL281188B2 (en) * | 2018-09-07 | 2025-08-01 | Arvinas Operations Inc | Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| AU2019348094B2 (en) * | 2018-09-30 | 2022-12-22 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| US11691984B2 (en) | 2018-10-12 | 2023-07-04 | The Scripps Research Institute | Compounds and methods for DCAF-mediated protein degradation |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| WO2020114482A1 (zh) * | 2018-12-06 | 2020-06-11 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP3922632A4 (en) * | 2019-02-07 | 2023-02-15 | Korea Research Institute of Chemical Technology | DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE |
| US11389438B2 (en) * | 2019-02-25 | 2022-07-19 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| CN111606883B (zh) | 2019-02-25 | 2023-05-09 | 上海科技大学 | 基于戊二酰亚胺骨架的含硫化合物及其应用 |
| US12186401B2 (en) | 2019-03-01 | 2025-01-07 | Ontario Institute for Cancer Research (OICR) and Sinai Health System | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2020214555A1 (en) | 2019-04-16 | 2020-10-22 | Northwestern University | Bifunctional compounds comprising apcin-a and their use in the treatment of cancer |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN113544130B (zh) * | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| WO2021016521A1 (en) * | 2019-07-25 | 2021-01-28 | Beth Israel Deaconess Medical Center, Inc. | Photo induced control of protein destruction |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| EP4034114A4 (en) * | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES |
| JP7307796B2 (ja) * | 2019-09-23 | 2023-07-12 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用 |
| WO2021061644A1 (en) * | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN114728071B (zh) * | 2019-11-13 | 2024-12-06 | 新旭生技股份有限公司 | 用于降解tau蛋白聚集体的化合物及其用途 |
| JP7629459B2 (ja) | 2019-11-19 | 2025-02-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物 |
| MX2022006861A (es) | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| CN110950877B (zh) * | 2019-12-11 | 2022-06-28 | 齐鲁工业大学 | 一种双检测荧光探针、制备方法及其在检测硫化氢和铜离子中的应用 |
| WO2021126973A1 (en) * | 2019-12-17 | 2021-06-24 | Orionis Biosciences, Inc. | Compounds modulating protein recruitment and/or degradation |
| US20230099031A1 (en) * | 2019-12-17 | 2023-03-30 | Orionis Biosciences, Inc. | Bifunctional agents for protein recruitment and/or degradation |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| EP4110772A4 (en) | 2020-02-26 | 2024-04-03 | Cullgen (Shanghai), Inc. | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| CN115803030A (zh) * | 2020-04-06 | 2023-03-14 | 阿维纳斯企业公司 | 用于kras靶向降解的化合物和方法 |
| CN115867554B (zh) | 2020-06-09 | 2025-09-02 | 普莱鲁德疗法有限公司 | Brm靶向化合物和相关使用方法 |
| AU2021293907A1 (en) * | 2020-06-17 | 2023-01-19 | Dana-Farber Cancer Institute, Inc. | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system |
| WO2021255213A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
| JP2023530030A (ja) | 2020-06-19 | 2023-07-12 | シーフォー セラピューティクス， インコーポレイテッド | Ｂｒａｆ分解剤 |
| KR102559329B1 (ko) * | 2020-07-02 | 2023-07-25 | 포항공과대학교 산학협력단 | 신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| AU2021311245A1 (en) | 2020-07-21 | 2023-03-09 | Ubix Therapeutics, Inc. | Compound for androgen receptor degradation, and pharmaceutical use thereof |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| WO2022031772A1 (en) * | 2020-08-07 | 2022-02-10 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
| JP2023536657A (ja) * | 2020-08-07 | 2023-08-28 | コーネル ユニバーシティー | タンパク質をｅ３リガーゼの媒介によって分解するための、治療上有用なｃｕｒｅ－ｐｒｏ分子、ならびにその作製方法及び使用方法 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN117062814A (zh) * | 2020-08-28 | 2023-11-14 | 阿维纳斯运营公司 | 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法 |
| WO2022056368A1 (en) | 2020-09-14 | 2022-03-17 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| KR102532692B1 (ko) * | 2021-03-15 | 2023-05-16 | (주)피알지에스앤텍 | 신경섬유종증 2형 증후군 예방 또는 치료용 조성물 |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| EP4320112B1 (en) | 2021-04-06 | 2025-05-14 | Bristol-Myers Squibb Company | Pyridinyl substituted oxoisoindoline compounds |
| KR20230171979A (ko) | 2021-04-16 | 2023-12-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Bcl6 단백질 분해의 조절제 및 관련 사용 방법 |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| TW202309039A (zh) | 2021-05-05 | 2023-03-01 | 美商百健Ｍａ公司 | 用於靶向布魯頓氏酪胺酸激酶降解之化合物 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| EP4351574B1 (en) | 2021-06-07 | 2026-03-04 | The General Hospital Corporation | Inhibitors of ttbk1 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| KR20240032010A (ko) | 2021-06-09 | 2024-03-08 | 더 스크립스 리서치 인스티튜트 | 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법 |
| EP4367113A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
| US20250018046A1 (en) | 2021-07-07 | 2025-01-16 | Biogen Ma Inc | Compounds for targeting degradation of irak4 proteins |
| WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
| US20240365736A1 (en) | 2021-09-01 | 2024-11-07 | Oerth Bio Llc | Compositions and methods for targeted degradation of proteins in a plant cell |
| CA3235512A1 (en) * | 2021-10-22 | 2023-04-27 | Xiaobao Yang | Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CN118574822A (zh) * | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 新型protac化合物 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024140638A1 (zh) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| CN121263417A (zh) | 2023-06-30 | 2026-01-02 | 金橘生物科技公司 | 取代的稠合三环胺化合物及其作为ras抑制剂的用途 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2024374420A1 (en) | 2023-11-02 | 2026-04-16 | Kumquat Biosciences Inc. | Degraders and uses thereof |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137500A1 (en) | 2023-12-21 | 2025-06-26 | Dana-Farber Cancer Institute, Inc. | Kinase inhibition and degradation |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025235298A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121735910A (zh) * | 2024-09-27 | 2026-03-27 | 上海交通大学 | 一种模块化的分子胶化合物库及其构建方法和应用 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000079I2 (de) | 1996-07-24 | 2010-08-12 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| EP1176959B1 (en) | 1999-05-05 | 2006-03-08 | Merck & Co., Inc. | Novel prolines as antimicrobial agents |
| WO2002020740A2 (en) | 2000-09-08 | 2002-03-14 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| JP2005507363A (ja) | 2001-02-16 | 2005-03-17 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 血管新生阻害トリペプチド、組成物およびそれらの使用方法 |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| BRPI0506883A (pt) | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| AU2005228950B2 (en) | 2004-03-23 | 2012-02-02 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| DK2253614T3 (da) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP-inhibitorer |
| KR100984459B1 (ko) | 2004-07-02 | 2010-09-29 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| DK1836201T4 (da) | 2004-12-20 | 2013-11-11 | Genentech Inc | Pyrrolidininhibitorer af IAP. |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| MX2007010371A (es) | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| UA95244C2 (ru) * | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| UA91560C2 (ru) | 2005-08-31 | 2010-08-10 | Селджин Корпорэйшн | Соединения ряда изоиндолимидов, их композиция и применение |
| AU2007226715A1 (en) | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| NZ572531A (en) | 2006-05-05 | 2011-09-30 | Univ Michigan | Bivalent smac mimetics and the uses thereof |
| AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| US20100203012A1 (en) | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| US8551955B2 (en) | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| CN103153335A (zh) | 2010-06-30 | 2013-06-12 | 布兰代斯大学 | 小分子靶定的蛋白质降解 |
| WO2012040527A2 (en) | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| CA2823837A1 (en) | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2012090104A1 (en) | 2010-12-31 | 2012-07-05 | Kareus Therapeutics, Sa | Methods and compositions for designing novel conjugate therapeutics |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| US9624213B2 (en) * | 2011-02-07 | 2017-04-18 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| EP2776409B1 (en) | 2011-11-09 | 2016-02-03 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| PL2797888T3 (pl) * | 2011-12-31 | 2016-12-30 | Połączone związki tricykliczne jako inhibitory kinazy raf | |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| US20150141470A1 (en) * | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2013170147A1 (en) | 2012-05-11 | 2013-11-14 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| BR112014029530A2 (pt) | 2012-05-30 | 2017-06-27 | Hoffmann La Roche | compostos, composição farmacêutica e uso de um composto |
| US9345740B2 (en) | 2012-07-10 | 2016-05-24 | Bristol-Myers Squibb Company | IAP antagonists |
| ES2742285T3 (es) | 2012-07-31 | 2020-02-13 | Novartis Ag | Marcadores asociados con la sensibilidad a inhibidores del doble minuto humano 2 (MDM2) |
| US9453048B2 (en) | 2012-08-09 | 2016-09-27 | Bristol-Myers Squibb Company | IAP antagonists |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| CA2930030A1 (en) | 2012-11-09 | 2014-05-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| WO2014100071A2 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| MX374513B (es) | 2013-03-14 | 2025-03-06 | Amgen Inc | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| US9637518B2 (en) | 2013-07-12 | 2017-05-02 | Bristol-Myers Squibb Company | IAP antagonists |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) * | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| BR112017028269A2 (pt) | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| BR112018068906A2 (pt) | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017254713C1 (en) | 2016-04-22 | 2021-04-29 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of EGFR and methods of use |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| WO2018098280A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
| KR20250117470A (ko) | 2016-12-23 | 2025-08-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
| JP2020505327A (ja) | 2016-12-23 | 2020-02-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| AU2018258581A1 (en) | 2017-04-28 | 2019-11-07 | Quartz Therapeutics, Inc. | RAF-degrading conjugate compounds |
-
2017
- 2017-12-22 KR KR1020257024694A patent/KR20250117470A/ko active Pending
- 2017-12-22 KR KR1020197021537A patent/KR102564201B1/ko active Active
- 2017-12-22 BR BR112019012878-6A patent/BR112019012878A2/pt active Search and Examination
- 2017-12-22 US US15/853,166 patent/US10723717B2/en active Active
- 2017-12-22 IL IL325835A patent/IL325835A/en unknown
- 2017-12-22 IL IL294423A patent/IL294423B2/en unknown
- 2017-12-22 EP EP17882647.5A patent/EP3558994A4/en active Pending
- 2017-12-22 MX MX2019007649A patent/MX2019007649A/es unknown
- 2017-12-22 KR KR1020237026280A patent/KR102839545B1/ko active Active
- 2017-12-22 AU AU2017382436A patent/AU2017382436C1/en active Active
- 2017-12-22 IL IL304704A patent/IL304704B1/en unknown
- 2017-12-22 CN CN201780087131.XA patent/CN110741004B/zh active Active
- 2017-12-22 WO PCT/US2017/068322 patent/WO2018119448A1/en not_active Ceased
- 2017-12-22 CN CN202311248251.7A patent/CN117510491A/zh active Pending
- 2017-12-22 CA CA3047784A patent/CA3047784A1/en active Pending
- 2017-12-22 JP JP2019534245A patent/JP7679173B2/ja active Active
-
2019
- 2019-06-17 IL IL267410A patent/IL267410A/en unknown
- 2019-06-21 MX MX2023009031A patent/MX2023009031A/es unknown
- 2019-07-23 CO CONC2019/0007894A patent/CO2019007894A2/es unknown
-
2021
- 2021-01-08 AU AU2021200099A patent/AU2021200099B2/en active Active
-
2023
- 2023-02-03 JP JP2023015526A patent/JP2023065395A/ja active Pending
-
2024
- 2024-10-16 JP JP2024180795A patent/JP2025016525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679173B2 (ja) | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 | |
| JP2020504741A5 (enExample) | ||
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| US11986531B2 (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| AU2025275145A1 (en) | Cereblon ligands and bifunctional compounds comprising the same | |
| CN119019369A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP2020505327A (ja) | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 | |
| JP2020505327A5 (enExample) | ||
| JP2020506914A5 (enExample) | ||
| BR112017028394A2 (en) | compound, composition, and methods for inducing degradation of a target protein in a cell and for treating a diseased condition or a diseased condition. | |
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| RU2782458C2 (ru) | Соединения и способы нацеленного расщепления полипептидов быстропрогрессирующей фибросаркомы |